| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015457 |
| Receipt No. | R000017971 |
| Official scientific title of the study | A Japanese prospective multi-center study of the effectiveness and safety of influenza vaccine. |
| Date of disclosure of the study information | 2014/10/20 |
| Last modified on | 2016/04/27 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | A Japanese prospective multi-center study of the effectiveness and safety of influenza vaccine. | |
| Title of the study (Brief title) | FLU STUDY'14-'15/JPA(I) | |
| Region |
|
|
| Condition | ||
| Condition | influenza | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluation of the effectiveness and the safety of influenza vaccine. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Incidence of influenza illness
Adverse event of vaccination |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Not applicable | |||
| Key exclusion criteria | Not applicable | |||
| Target sample size | ||||
| Research contact person | |
| Name of lead principal investigator | Norio Iwaki |
| Organization | Japan Physicians Association |
| Division name | Influenza study group |
| Address | 1-2-2 Hitotsubashi Chiyoda-ku, Tokyo-to, Japan |
| TEL | 03-5224-6110 |
| jpa@oregano.ocn.ne.jp | |
| Public contact | |
| Name of contact person | Naoki Kawai |
| Organization | Japan Physicians Association |
| Division name | Influenza study group |
| Address | 1-2-2 Hitotsubashi Chiyoda-ku, Tokyo-to, Japan |
| TEL | 03-5224-6110 |
| Homepage URL | |
| jpa@oregano.ocn.ne.jp | |
| Sponsor | |
| Institute | Influenza study group, Japan Physicians Association |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | http://www.japha.jp |
| Results | The efficacy and the safety of the influenza vaccine. |
| Other related information | Register influenza vaccine recipients group and the non-vaccinated group.
Compare a number of affected individuals with vaccine recipients and non-vaccinated. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017971 |